← Back to Search

Ferumoxytol for Pulmonary Embolism

Phase 1
Waitlist Available
Led By Andrew M Siedlecki, MD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial seeks to improve the care of patients with suspected pulmonary embolism and renal insufficiency by providing them with state of the art imaging.

Eligible Conditions
  • Pulmonary Embolism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pulmonary embolus

Side effects data

From 2017 Phase 4 trial • 296 Patients • NCT01227616
38%
Gastrointestinal disorders
33%
Infections and infestations
31%
Injury, poisoning and procedural complications
29%
General disorders and administration site conditions
21%
Respiratory, thoracic and mediastinal disorders
20%
Musculoskeletal and connective tissue disorders
19%
Vascular disorders
18%
Nervous system disorders
16%
Metabolism and nutrition disorders
15%
Cardiac disorders
11%
Nausea
11%
Diarrhoea
10%
Skin and subcutaneous tissue disorders
9%
Hypotension
9%
Psychiatric disorders
8%
Vomiting
8%
Muscle spasms
8%
Pyrexia
7%
Arteriovenous fistula site complication
7%
Blood and lymphatic system disorders
7%
Upper respiratory tract infection
7%
Fluid overload
7%
Pain in extremity
7%
Hypertension
6%
Urinary tract infection
6%
Hyperkalaemia
6%
Investigations
6%
Pruritus
6%
Abdominal pain
6%
Cough
6%
Dyspnoea
6%
Pneumonia
5%
Sepsis
5%
Non-cardiac chest pain
5%
Dizziness
4%
Arteriovenous fistula thrombosis
4%
Fall
4%
Acute respiratory failure
4%
Arthralgia
4%
Headache
4%
Anaemia
3%
Mental status changes
3%
Pulmonary oedema
3%
Cardiac failure congestive
3%
Cellulitis
2%
Angina pectoris
2%
Gastrointestinal haemorrhage
2%
Hip fracture
2%
Cardiac arrest
2%
Acute myocardial infarction
2%
Pleural effusion
2%
Cardio-respiratory arrest
1%
Hypoglycaemia
1%
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
1%
Immune system disorders
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ferumoxytol
Iron Sucrose

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Patients with a clinical concern for pulmonary embolus but not able to receive iodinated contrast will be enrolled. Ferumoxytol will be administered as a contrast agent in coordination with magnetic resonance angiography to identify patency of the cardiopulmonary vasculature.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ferumoxytol
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,608 Previous Clinical Trials
11,469,876 Total Patients Enrolled
21 Trials studying Pulmonary Embolism
811,526 Patients Enrolled for Pulmonary Embolism
Andrew M Siedlecki, MDPrincipal InvestigatorBrigham and Women's Hospital
2 Previous Clinical Trials
46 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
Andrew Michael Siedlecki 2018. "Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03173066.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top